Maria Skłodowska-Curie National Research Institute of Oncology (NRIO)
uitklapper, klik om te openen
Partner Information uitklapper, klik om te openen
Maria Skłodowska-Curie National Research Institute of Oncology (NRIO) has branches in Warsaw, Cracow and Gliwice, of which the latter is involved in STOPSTORM. Between 2013 and 2019, NRIO took part in nearly 60 scientific and research projects financed from external funds.
The Gliwice Branch is a high volume tertiary cancer centre that houses one of the largest radiotherapy department in Europe, with an average of 7000-8000 patients undergoing radiotherapy annually. The Radiotherapy Department is equipped with several accelerators capable of performing radiosurgical procedures and the team has great experience in intra- and extracranial stereotactic radiosurgery for primary and metastatic tumors and for functional diseases like trigeminal neuralgia or Parkinson Disease). NRIO in Gliwice has a team of medical physicists is experienced in stereotactic radiotherapy, an array of CT, MR and PET scanners, and an in-house cyclotron with automated radiosynthesis equipment for PET tracer production.
NRIO works in close partnership with cardiology departments from other institutes and has a cardio-oncologic team providing special care for patients with cardiac diseases, including cardiac monitoring during radiotherapy and/or MR imaging in patients with cardiac implantable electronic devices (CIEDs). This has resulted in the formulation of Polish recommendations on radiotherapy in patients with CIEDs published recently.
NRIO will collaborate with GCM on a soon-to-be-approved national clinical study focused on patients with recurrent VTs (SMART-VT trial). A direct cooperation between GCM and NRIO will be continued within the scope of the STOPSTORM trial.
Personnel uitklapper, klik om te openen
Dr. Sławomir Blamek
Dr. Sławomir Blamek is an Associate Professor and radiation oncologist at NRIO. He is also a Presidium Member of the local Ethics Committee. Dr. Blamek will be the local primary investigator. His role includes leading the WP3, including the design of the study protocol, supervision of the patient treatment, quality control of radiotherapy planning, supervision of data collection, communication with GCM, and coordination of the STOPSTORM initiative in Poland.
Dr. Marcin Miszczyk
Dr. Marcin Miszczyk obtained his PhD in 2020 at the Wrocław Medical University and currently works as a postdoctoral fellow at Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, specializing in stereotactic and functional radiosurgery. He is the author of the first Polish clinical trial regarding radiosurgery in the treatment of ventricular tachycardia, and the radiation oncologist behind the first treatment performed in Poland. Dr. Miszczyk is a member of the trial management board, as well as credentialing audit committee, and part of WP1. Within the national trials, dr Miszczyk is responsible for radiotherapy planning and treatment delivery.
Dr. Tomasz Latusek
Dr. Tomasz Latusek is a radiation oncology resident responsible for patient treatment, including radiotherapy planning, treatment delivery, data collection and participation in WP4.
Dr. Aleksandra Grządziel
Dr. Aleksandra Grządziel is a medical physicist responsible for radiotherapy planning and participation in WP4.
Dr. Bartłomiej Tomasik, MD PhD
Dr. Bartłomiej Tomasik, MD PhD is a radiation oncologist at the Department of Radiotherapy at Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Gliwice, Poland. He has a solid background in the field of biostatistics - he did his PhD at the Department of Biostatistics and Translational Medicine, Medical University of Łódź, Poland. After obtaining PhD, he underwent his postdoctoral internship at the Dana- Farber Cancer Institute/Harvard Medical School (Boston, MA, USA). As a radiation oncologist, Dr. Tomasik is working on novel biomarkers for radiation-related toxicity, he is also a member of the Young Committee of the European Society for Radiotherapy and Oncology (ESTRO). Within STOPSTORM, he works as a co-leader of Work Package 5 - “Analysis and evaluation”, together with Dr. Martin Fast.
- Tajstra M, Blamek S, Niedziela JT, et al. Patients with cardiac implantable electronic devices undergoing radiotherapy in Poland. Expert opinion of the Heart Rhythm Section of the Polish Cardiac Society and the Polish Society of Radiation Oncology. Kardiol Pol 2019; 77: 1106-16.
- Tajstra M, Gadula-Gacek E, Buchta P, Blamek S, Gasior M, Kosiuk. Effect of Therapeutic Ionizing Radiation on Implantable Electronic Devices: Systematic Review and Practical Guidance. J Cardiovasc Electrophysiol 2016; 27: 1247-51.
- Gramatyka M, Boguszewicz ᴌ, Ciszek M, Gabryś D, Kulik R, Sokół M. Metabolic changes in mice cardiac tissue after low-dose irradiation revealed by 1H NMR spectroscopy. J Radiat Res 2020; 26: 14-26. Jan 23;61(1):14-26. doi: 10.1093/jrr/rrz079.4.
- Miszczyk L, Namysł-Kaletka A, Napieralska A, et al. Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures. Technol Cancer Res Treat 2019; 18: 1533033819870815.
- Dworzecki T, Idasiak A, Syguła D, Dworzecka U, Suwiński R. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients. Neoplasma 2012; 59: 114-20.